Galmed Pharmaceuticals Revenue vs. Shares Outstanding
| GLMD Stock | USD 2.82 0.06 2.08% |
Total Revenue | First Reported 2012-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 243.5 K |
For Galmed Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Galmed Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Galmed Pharmaceuticals utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Galmed Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Galmed Pharmaceuticals over time as well as its relative position and ranking within its peers.
Galmed |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 69.72 | Return On Assets (0.29) | Return On Equity (0.53) |
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Galmed Pharmaceuticals Shares Outstanding vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Galmed Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Galmed Pharmaceuticals value to that of its competitors to determine the firm's financial worth. Galmed Pharmaceuticals is currently under evaluation in revenue category among its peers. It is rated below average in shares outstanding category among its peers . At present, Galmed Pharmaceuticals' Total Revenue is projected to increase significantly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Galmed Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Galmed Revenue vs. Competition
Galmed Pharmaceuticals is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 476.39 Million. Galmed Pharmaceuticals adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.
Galmed Shares Outstanding vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Galmed Pharmaceuticals |
| = | null |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Galmed Pharmaceuticals |
| = | 1.66 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Galmed Shares Outstanding Comparison
Galmed Pharmaceuticals is currently under evaluation in shares outstanding category among its peers.
Galmed Pharmaceuticals Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Galmed Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Galmed Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Galmed Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Galmed Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -454 K | -431.3 K | |
| Operating Income | 7.5 M | 7.9 M | |
| Income Before Tax | -6.9 M | -7.3 M | |
| Total Other Income Expense Net | -14.4 M | -13.7 M | |
| Net Loss | -6.9 M | -7.3 M | |
| Income Tax Expense | -15 M | -14.2 M | |
| Net Loss | -7.5 M | -7.9 M | |
| Net Loss | -25.9 M | -24.6 M | |
| Net Interest Income | 745 K | 775.1 K | |
| Interest Income | 375 K | 747.7 K | |
| Change To Netincome | 1.6 M | 2.2 M | |
| Net Loss | (30.05) | (31.55) | |
| Income Quality | 0.89 | 0.67 | |
| Net Income Per E B T | 1.20 | 1.09 |
Galmed Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Galmed Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Galmed Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Galmed Pharmaceuticals' important profitability drivers and their relationship over time.
Use Galmed Pharmaceuticals in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Galmed Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Galmed Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Galmed Pharmaceuticals Pair Trading
Galmed Pharmaceuticals Pair Trading Analysis
The ability to find closely correlated positions to Galmed Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Galmed Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Galmed Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Galmed Pharmaceuticals to buy it.
The correlation of Galmed Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Galmed Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Galmed Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Galmed Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Galmed Pharmaceuticals position
In addition to having Galmed Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Climate Change Thematic Idea Now
Climate Change
Large and medium sized entities that are committing to fully or partially replace some traditional services or products with renewables sources of energy in order to combat global climate change. The Climate Change theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Climate Change Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Risk vs Return Analysis. For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
To fully project Galmed Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Galmed Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Galmed Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.